About Contact Us Careers

Short-acting Beta Agonists Market Size and Forecast, by Dosage Form (Injectable, Solution, Tablet, Syrup); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores); Application (Asthma, Chronic Obstructive Pulmonary Disease) - Growth Trends, Key Players, Regional Analysis 2026-2035

  • Report ID: 5820
  • Published Date: Nov 28, 2025
  • Report Format: PDF, PPT

Short-acting Beta Agonists Market Outlook:

Short-acting Beta Agonists Market size was valued at USD 868.04 million in 2025 and is likely to cross USD 2.11 billion by 2035, expanding at more than 9.3% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of short-acting beta agonists is assessed at USD 940.69 million.

Short-acting Beta Agonists Market 11
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

The escalating prevalence of respiratory disorders worldwide is propelling the market’s growth. With 454.6 million cases (417.4–499.1) worldwide, chronic respiratory disorders ranked as the third most common cause of mortality in 2019. They were responsible for 4.0 million deaths (95% uncertainty interval 3.6–4.3) worldwide. As conditions like asthma and chronic obstructive pulmonary disease(COPD) become more widespread, the demand for quick-relief medications, such as SABAs, continues to surge. As observed by Research Nester analysts, globally, the prevalence of COPD was predicted to be 10.6% in 2020 for both males and females, or 480 million cases. This driver is fuelled by environmental factors, lifestyle changes, and an aging population, necessitating effective bronchodilators for immediate symptom relief. As a result, pharmaceutical companies are witnessing increased demand for SABAs, positioning them as a pivotal solution in addressing the rising global burden of respiratory diseases.

In addition, when it comes to death rates, chronic obstructive pulmonary disease (COPD) is ranked third worldwide. The increasing prevalence of lung illnesses worldwide is predicted to drive short-acting beta agonists market expansion. People who currently reside in or were raised in urban regions are more prone to experience these illnesses.

Key Short-acting Beta Agonists Market Insights Summary:

  • Regional Insights:

    • North America is anticipated to secure a 42% share by 2035 in the short-acting beta agonists market, bolstered by the presence of major industry players.
    • Europe is projected to hold a substantial share by 2035, sustained by its emphasis on advanced inhalation technologies.

  • Segment Insights:

    • The solution segment is projected to capture a 42% share by 2035 in the short-acting beta agonists market, propelled by the rapid-relief benefits of inhalable drug delivery.
    • The retail pharmacies segment is expected to command the leading share by 2035, supported by their widespread accessibility for immediate SABA availability.

  • Key Growth Trends:

    • Increased Awareness and Diagnosis of Respiratory Conditions
    • Technological Advancements in Inhalation Devices

  • Major Challenges:

    • Stringent Regulatory Approval Processes
    • The availability of generic versions of Short-acting Beta-Agonists poses

  • Key Players: Teva Pharmaceutical Industries Ltd., Viatris Inc., F.Hoffmann-La Roche Ltd, GlaxoSmithKline plc., Cipla Inc., Merck & Co., Inc., Schering-Plough Corporation, AstraZeneca, Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited.

Global Short-acting Beta Agonists Market Forecast and Regional Outlook:

  • Market Size & Growth Projections:

    • 2025 Market Size: USD 868.04 million
    • 2026 Market Size: USD 940.69 million
    • Projected Market Size: USD 2.11 billion by 2035
    • Growth Forecasts: 9.3%

  • Key Regional Dynamics:

    • Largest Region: North America (42% Share by 2035)
    • Fastest Growing Region: Europe
    • Dominating Countries: United States, Germany, United Kingdom, Japan, China
    • Emerging Countries: India, Brazil, South Korea, Mexico, Indonesia

    • Last updated on : 28 November, 2025

Growth Drivers

  • Increased Awareness and Diagnosis of Respiratory Conditions- Growing awareness about respiratory health, coupled with improved diagnostic capabilities, leads to early detection and treatment of respiratory disorders. This increased awareness among both healthcare professionals and the general population drives the demand for SABAs as a crucial component of managing acute respiratory symptoms.

  • Technological Advancements in Inhalation Devices- Ongoing advancements in inhalation device technologies contribute to the growth of the SABA market. Improved and user-friendly inhalers enhance the efficiency and ease of medication delivery, promoting patient adherence. Innovations such as smart inhalers and breath-actuated devices further enhance the precision and effectiveness of Short-acting Beta Agonists administration.

  • Patient-Centric Treatment Approaches- The shift towards patient-centric healthcare approaches emphasizes personalized treatment plans. In total, 60.9% (95% CI 57.1%–64.5%) of patients had care that was focused on their needs. Short-acting Beta Agonists, known for their rapid onset of action and immediate relief, align with this trend, as healthcare providers increasingly prescribe respiratory drugs tailored to individual patient needs, contributing to the short-acting beta agonists market growth.

Challenges

  • Stringent Regulatory Approval Processes- The regulatory hurdles associated with gaining approvals for new Short-acting Beta-Agonists formulations or delivery devices can be time-consuming and costly. Stringent regulations can delay market entry for novel products, hindering innovation and potentially limiting the variety of treatment options available to patients.

  • The availability of generic versions of Short-acting Beta-Agonists poses a challenge to the market growth.

  • SABA side effects may affect adherence. Safer formulations, monitoring, and research are crucial for short-acting beta agonists market confidence.

Short-acting Beta Agonists Market Size and Forecast:

Report Attribute Details

Base Year

2025

Forecast Year

2026-2035

CAGR

9.3%

Base Year Market Size (2025)

USD 868.04 million

Forecast Year Market Size (2035)

USD 2.11 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Short-acting Beta Agonists Market Segmentation:

Dosage Form Segment Analysis

The solution segment is predicted to account for 42% share of the global short-acting beta agonists market. The segment’s dominance is primarily due to the nature of respiratory conditions like asthma and COPD, where direct delivery to the lungs provides rapid relief. Between 2001 and 2021, the prevalence of adult asthma increased from 6.9% to 8.0%. Inhalable forms offer a quick onset of action, targeting the affected airways directly. While injectable forms, tablets, and syrups may have their applications, inhalable solutions and aerosols are generally preferred for their effectiveness, convenience, and reduced systemic side effects. Patients find inhalable forms more user-friendly and compliant, contributing to their widespread adoption. Additionally, advancements in inhalation device technology further enhance the appeal of these dosage forms, reinforcing their anticipated majority market share.

Distribution Channel Segment Analysis

Retail pharmacies segment is anticipated to hold the majority of the revenue share in the global short-acting beta agonists market. This is attributed to the widespread accessibility of retail pharmacies, making SABA medications readily available to a larger patient population. Retail pharmacies offer convenience, ease of access, and personalized consultation services, promoting patient adherence to respiratory treatments. Additionally, the established presence of retail chains and their ability to provide immediate relief medications aligns with the urgent and episodic nature of conditions like asthma, contributing to the expected dominance of this distribution channel.

Our in-depth analysis of the global short-acting beta agonists market includes the following segments:

        Dosage Form
  • Injectable
  •  Solution
  •  Tablet
  •  Syrup

        Distribution Channel
  • Hospital Pharmacies
  •  Retail Pharmacies
  •  Online Pharmacies
  •  Drug Stores

          Application

  • Asthma
  • Chronic Obstructive Pulmonary Disease
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Short-acting Beta Agonists Market - Regional Analysis

North American Market Insights

North America industry is anticipated to account for largest revenue share of 42% by 2035. The region's growth is attributed to the presence of key players in the region. The market is influenced by factors such as the increasing prevalence of respiratory disorders, advancements in inhalation technology, and a growing awareness of respiratory health. Regulatory approvals, generic competition, and regional healthcare policies significantly impact market dynamics. As a crucial component of respiratory care, the North American Short-acting Beta-Agonists market continues to evolve with a focus on innovation, accessibility, and patient-centric solutions. For instance, in the United States, chronic lung diseases such as asthma and COPD, which encompass emphysema and chronic bronchitis, affect about 34 million individuals.

European Market Insights

European short-acting beta agonists market is estimated to hold a significant revenue share. The market for Short-acting Beta Agonists (SABAs) is influenced by a variety of factors, including the growing prevalence of respiratory disorders, advancements in inhalation technologies, and regulatory approvals. Other factors such as generic competition, regional variations, and healthcare policies also impact market trends. The European SABA market is highly focused on innovation in inhalation therapy and patient-centric solutions. With an emphasis on improving respiratory health and enhancing treatment accessibility, the market is constantly evolving to meet the diverse needs of patients across the region. This focus on innovation and patient-centric solutions has helped to establish Europe as a leader in the global SABAs market.

Short-acting Beta Agonists Market 22
Get Strategic Analysis by Region Now: Request Free Sample PDF

Short-acting Beta Agonists Market Players:

    Bayer AG

    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • F. Hoffmann-La Roche Ltd  
    • GlaxoSmithKline plc.
    • Cipla Inc. 
    • Merck & Co., Inc.
    • Schering-Plough Corporation
    •  AstraZeneca
    • Johnson & Johnson Services, Inc.

Recent Developments

  • FDA approved Airsupra inhalation aerosol for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma attacks in patients 18 years and older. It is the first combination of an inhaled corticosteroid and a short-acting beta-agonist to be approved in the U.S. and the first product containing an ICS to be approved in the U.S. as a reliever treatment for asthma.
  • Bayer has acquired Blackford Analysis Ltd, a global imaging AI platform and solutions provider. Blackford's clinical application ecosystem for imaging and analytics is now a wholly-owned subsidiary of Bayer, but Blackford will continue to operate independently.
  • Report ID: 5820
  • Published Date: Nov 28, 2025
  • Report Format: PDF, PPT
  • Explore a preview of key market trends and insights
  • Review sample data tables and segment breakdowns
  • Experience the quality of our visual data representations
  • Evaluate our report structure and research methodology
  • Get a glimpse of competitive landscape analysis
  • Understand how regional forecasts are presented
  • Assess the depth of company profiling and benchmarking
  • Preview how actionable insights can support your strategy

Explore real data and analysis

Download Free Sample Report

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of short-acting beta agonists is assessed at USD 940.69 million.

The global short-acting beta agonists market size was valued at over USD 868.04 million in 2025 and is expected to expand at a CAGR of around 9.3%, surpassing USD 2.11 billion revenue by 2035.

North America is anticipated to secure a 42% share by 2035 in the short-acting beta agonists market, bolstered by the presence of major industry players.

Key players in the market include Teva Pharmaceutical Industries Ltd., Viatris Inc., F.Hoffmann-La Roche Ltd, GlaxoSmithKline plc., Cipla Inc., Merck & Co., Inc., Schering-Plough Corporation, AstraZeneca, Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited.

Short-acting Beta Agonists Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Get a Free Sample

See how top U.S. companies are managing market uncertainty — get your free sample with trends, challenges, macroeconomic factors, charts, forecasts, and more.

Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos